Market Summary
USD7.97-0.16
Market Closed-1.97%
RXRX Stock Price
RXRX RSI Chart
RXRX Valuation
RXRX Price/Sales (Trailing)
RXRX Profitability
RXRX Fundamentals
RXRX Revenue
RXRX Earnings
Price Action
52 Week Range
16.75
(Low)(High)
Last 7 days
-7.3%
Last 30 days
-12.2%
Last 90 days
8.3%
Trailing 12 Months
-26.6%
RXRX Financial Health
RXRX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for RXRX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-15 | Virani Shafique | acquired | 39,960 | 2.22 | 18,000 | chief business officer |
2023-09-15 | Gibson Christopher | gifted | - | - | -10,000 | chief executive officer |
2023-09-15 | Gibson Christopher | acquired | - | - | 10,000 | chief executive officer |
2023-09-15 | Virani Shafique | sold | -155,880 | 8.66 | -18,000 | chief business officer |
2023-09-13 | Secora Michael | sold | -217,318 | 8.6927 | -25,000 | chief financial officer |
2023-09-13 | Secora Michael | acquired | 83,250 | 2.22 | 37,500 | chief financial officer |
2023-09-12 | Secora Michael | sold | -210,632 | 8.4253 | -25,000 | chief financial officer |
2023-09-12 | Secora Michael | acquired | 83,250 | 2.22 | 37,500 | chief financial officer |
2023-09-06 | Gibson Christopher | acquired | - | - | 20,000 | chief executive officer |
2023-09-06 | Gibson Christopher | sold | -8,836 | 8.8363 | -1,000 | chief executive officer |
Which funds bought or sold RXRX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | unchanged | - | 73.00 | 680 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 4.2 | 3,422 | 23,924 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | 139,000 | 1,303,000 | 0.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 60.49 | 524,899 | 1,183,190 | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 9.76 | 1,568,570 | 8,408,570 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 7.91 | 744,218 | 4,313,520 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 27.81 | 254,994 | 846,142 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | unchanged | - | 246,929 | 2,305,700 | -% |
2023-08-15 | CENTAURUS FINANCIAL, INC. | added | 20.13 | 25,000 | 99,000 | 0.01% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | reduced | -0.12 | 274,000 | 2,578,000 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of RECURSION PHARMACEUTICALS
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| May 22, 2023 | kinnevik ab (publ) | 5.6% | 10,405,668 | SC 13G | |
| Feb 14, 2023 | lux capital management, llc | 3.3% | 6,004,722 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 5.54% | 10,057,363 | SC 13G | |
| Feb 03, 2023 | blackrock inc. | 5.9% | 10,667,624 | SC 13G | |
| Jan 24, 2023 | baillie gifford & co | 13.66% | 24,820,850 | SC 13G/A | |
| Oct 31, 2022 | mubadala investment co pjsc | 6.3% | 11,291,937 | SC 13D/A | |
| Feb 14, 2022 | data collective iv, l.p. | 3.7% | 5,941,120 | SC 13G | |
| Feb 14, 2022 | lux capital management, llc | 8.2% | 13,021,519 | SC 13G |
Recent SEC filings of RECURSION PHARMACEUTICALS
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 21, 2023 | 4 | Insider Trading | |
| Sep 19, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 15, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 14, 2023 | 4 | Insider Trading | |
| Sep 13, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 12, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 08, 2023 | 4 | Insider Trading | |
| Sep 07, 2023 | 4 | Insider Trading |
RECURSION PHARMACEUTICALS News
Returns for RXRX
Cumulative Returns on RXRX
Risks for RXRX
What is the probability of a big loss on RXRX?
96.9%
Probability that RECURSION PHARMACEUTICALS stock will be more than 20% underwater in next one year
96.9%
Probability that RECURSION PHARMACEUTICALS stock will be more than 30% underwater in next one year.
86.7%
Probability that RECURSION PHARMACEUTICALS stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does RXRX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if RECURSION PHARMACEUTICALS was unfortunately bought at previous high price.
Drawdowns
Financials for RECURSION PHARMACEUTICALS
Income Statement (Last 12 Months)(In Thousands)
| Income Statement (Last 12 Months) | (In Thousands) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
| Revenue | 7.2% | 49,987 | 46,644 | 39,843 | 28,700 | 18,074 | 12,949 | 10,178 | 10,336 | 8,827 | 25,221 | 3,962 | 3,551 | 3,141 | 2,730 | 2,319 |
| Operating Expenses | - | - | - | - | - | - | - | 192,953 | 153,732 | 128,295 | 103,220 | 88,577 | 80,407 | 73,612 | 73,612 | 64,760 |
| S&GA Expenses | 8.5% | 90,490 | 83,399 | 81,599 | 80,962 | 77,164 | 69,819 | 57,682 | 46,055 | 37,329 | 28,634 | 25,258 | 23,579 | 21,440 | 22,244 | 18,951 |
| R&D Expenses | 9.8% | 186,553 | 169,932 | 155,696 | 160,008 | 152,418 | 143,603 | 135,271 | 107,677 | 90,966 | 74,586 | 63,319 | 56,828 | 52,172 | 51,368 | 45,809 |
| Interest Expenses | -3.7% | 52.00 | 54.00 | 55.00 | 57.00 | 168 | 440 | 680 | 831 | 807 | 937 | 989 | 1,097 | 1,444 | 1,224 | 485 |
| Net Income | -4.5% | -259,990 | -248,824 | -239,476 | -246,917 | -233,900 | -211,741 | -186,479 | -147,312 | -123,757 | -99,299 | -87,006 | -81,653 | -74,734 | -73,696 | -61,879 |
| Net Income Margin | 100.0% | - | -5.33* | -6.01* | -8.60* | -10.38* | -3.94* | -18.32* | -2.88* | -2.49* | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -272,120 | -120,583 | -133,478 | -113,428 | -75,195 | -198,412 | -127,904 | -105,432 | -117,048 | -74,821 | -74,821 | -71,668 | -74,004 | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
| Assets | 6.3% | 667 | 627 | 701 | 612 | 673 | 734 | 610 | 659 | 699 | 272 | 299 |
| Current Assets | -12.4% | 431 | 492 | 570 | 482 | 546 | 619 | 535 | 601 | 648 | 222 | 266 |
| Cash Equivalents | -14.2% | 406 | 473 | 550 | 455 | 464 | 518 | 295 | 405 | 643 | 219 | 267 |
| Net PPE | -0.3% | 90.00 | 90.00 | 88.00 | 86.00 | 82.00 | 71.00 | 65.00 | 55.00 | 49.00 | 45.00 | 26.00 |
| Goodwill | 7455.1% | 61.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | - | - | - | 1.00 |
| Liabilities | 0.3% | 198 | 197 | 215 | 223 | 235 | 241 | 67.00 | 60.00 | 56.00 | 57.00 | 57.00 |
| Current Liabilities | 23.7% | 114 | 92.00 | 100 | 83.00 | 97.00 | 86.00 | 47.00 | 43.00 | 30.00 | 27.00 | 23.00 |
| Shareholder's Equity | 9.0% | 469 | 430 | 486 | 388 | 438 | 494 | 543 | 599 | 643 | - | - |
| Retained Earnings | -10.9% | -781 | -704 | -639 | -582 | -521 | -456 | -400 | -335 | -287 | -244 | -213 |
| Additional Paid-In Capital | 10.2% | 1,251 | 1,135 | 1,125 | 970 | 959 | 950 | 943 | 934 | 930 | 11.00 | 7.00 |
| Shares Outstanding | 7.5% | 207 | 192 | 191 | 174 | 172 | 171 | 170 | 169 | 138 | 23.00 | 22.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
| Cashflow From Operations | -2.5% | -240,072 | -234,228 | -83,524 | -99,934 | -78,441 | -50,471 | -158,614 | -88,883 | -75,291 | -58,337 | -45,399 | -71,962 | -69,032 | -71,268 | -57,042 |
| Share Based Compensation | 19.7% | 37,227 | 31,091 | 27,909 | 24,555 | 19,011 | 18,653 | 14,842 | 11,689 | 9,396 | 4,848 | 4,292 | 4,139 | 4,068 | 5,060 | 1,385 |
| Cashflow From Investing | -15.7% | 37,612 | 44,605 | 193,249 | 148,985 | -97,872 | -109,024 | -271,744 | -224,092 | -33,645 | -27,472 | -8,740 | -5,532 | -1,446 | -2,736 | -3,910 |
| Cashflow From Financing | 0.7% | 155,302 | 154,183 | 154,345 | 10,885 | -2,547 | 458,490 | 458,540 | 464,779 | 705,595 | 242,272 | 246,135 | 314,800 | 12,758 | 23,988 | 120,410 |
RXRX Income Statement
2023-06-30Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue | ||||
| Revenue | $ 11,017 | $ 7,674 | $ 23,151 | $ 13,007 |
| Operating costs and expenses | ||||
| Cost of revenue | 9,382 | 14,227 | 21,829 | 22,026 |
| Research and development | 55,060 | 38,439 | 101,737 | 70,880 |
| General and administrative | 28,290 | 21,199 | 51,165 | 42,273 |
| Total operating costs and expenses | 92,732 | 73,865 | 174,731 | 135,179 |
| Loss from operations | (81,715) | (66,191) | (151,580) | (122,172) |
| Other income, net | 4,989 | 631 | 9,527 | 633 |
| Net loss | $ (76,726) | $ (65,560) | $ (142,053) | $ (121,539) |
| Per share data | ||||
| Net loss per share of Class A, B and Exchangeable common stock, basic (in dollars per share) | $ (0.38) | $ (0.38) | $ (0.71) | $ (0.71) |
| Net loss per share of Class A, B and Exchangeable common stock, diluted (in dollars per share) | $ (0.38) | $ (0.38) | $ (0.71) | $ (0.71) |
| Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares) | 201,415,475 | 172,212,390 | 198,957,804 | 171,455,595 |
| Weighted-average shares (Class A, B and Exchangeable) outstanding, diluted (in shares) | 201,415,475 | 172,212,390 | 198,957,804 | 171,455,595 |
| Operating revenue | ||||
| Revenue | ||||
| Revenue | $ 11,016 | $ 7,653 | $ 23,150 | $ 12,952 |
| Grant revenue | ||||
| Revenue | ||||
| Revenue | $ 1 | $ 21 | $ 1 | $ 55 |
RXRX Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 405,870 | $ 549,912 |
| Restricted cash | 3,325 | 1,280 |
| Other receivables | 3,051 | 2,753 |
| Other current assets | 18,774 | 15,869 |
| Total current assets | 431,020 | 569,814 |
| Restricted cash, non-current | 7,629 | 7,920 |
| Property and equipment, net | 89,768 | 88,192 |
| Operating lease right-of-use assets | 34,899 | 33,255 |
| Intangible assets, net | 42,757 | 1,306 |
| Goodwill | 60,516 | 801 |
| Other assets, non-current | 110 | 0 |
| Total assets | 666,699 | 701,288 |
| Current liabilities | ||
| Accounts payable | 2,086 | 4,586 |
| Accrued expenses and other liabilities | 32,873 | 32,904 |
| Unearned revenue | 73,105 | 56,726 |
| Notes payable | 676 | 97 |
| Operating lease liabilities | 5,219 | 5,952 |
| Total current liabilities | 113,959 | 100,265 |
| Unearned revenue, non-current | 32,436 | 70,261 |
| Notes payable, non-current | 1,155 | 536 |
| Operating lease liabilities, non-current | 45,850 | 44,420 |
| Deferred tax liabilities | 4,336 | 0 |
| Total liabilities | 197,736 | 215,482 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of June 30, 2023 and December 31, 2022; 206,737,332 shares (Class A 195,051,012, Class B 7,679,871 and Exchangeable 4,006,449) and 191,022,864 shares (Class A 183,209,655, Class B 7,813,209 and Exchangeable 0) issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 2 | 2 |
| Additional paid-in capital | 1,250,570 | 1,125,360 |
| Accumulated deficit | (781,609) | (639,556) |
| Total stockholders’ equity | 468,963 | 485,806 |
| Total liabilities and stockholders’ equity | $ 666,699 | $ 701,288 |
Chistopher C. Gibson
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.